2012
Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer
El-Sahwi KS, Schwartz PE, Santin AD. Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer. Expert Review Of Anticancer Therapy 2012, 12: 41-49. PMID: 22149431, PMCID: PMC3287395, DOI: 10.1586/era.11.192.Peer-Reviewed Original ResearchConceptsType II endometrial cancerUterine serous cancerEndometrial cancerSerous cancerAggressive variantType I endometrial cancerFemale genital malignanciesUterine serous carcinomaOlder patientsGenital malignanciesMost recurrencesBetter prognosisSerous carcinomaEndometrial tumorsAggressive subsetEarly diagnosisTherapeutic markersMost carcinomasCancerCarcinomaMarkersHypertensionPostmenopausalObesityPatients
2011
erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy
ElSahwi KS, Santin AD. erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy. Obstetrics And Gynecology International 2011, 2011: 128295. PMID: 21876697, PMCID: PMC3159302, DOI: 10.1155/2011/128295.Peer-Reviewed Original ResearchUterine serous adenocarcinomaERBB2 overexpressionEndometrial cancerCommon female genital tract malignancyFemale genital tract malignanciesType I endometrial cancerGenital tract malignanciesUterine serous cancerViable treatment optionSerous cancerStandard chemotherapyWorse survivalLymph nodesTrastuzumab therapyBetter prognosisDistant metastasisSerous adenocarcinomaTreatment optionsCase reportRecurrent casesBreast cancerHumanized mAbTrastuzumab activityType II variantCancer relapse